1CDC. 1993 revised classification system tot HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992；41 (RR-17).
2Perelson AS, Neumann AU, Markowitz M, ct al. HIV-1 dynamics in vivo:virion clearance rate, infected cell life-span, and vital generation time. Science 1996； 217: 1582.
3Mellors J, Munoz A, Giorgi JV, et at. Plasma viral and CD4 lymphocytes as prognostic markers in H1V-I infection. Ann Intem Med. In press 1997.
4Kaplan JE. Masur H. Holmes KK et al. USPHS/IDSA guidelines for the prevention, of opportunistic infections in persons infected with human immunodeficiency virus: a ummary. Ann Intem Med 1996； 124: 349.
5Kaplan JE, Masur H, Holmes KK, et al. USPHS/DSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. Clin Infect Dis 1995； 21 (Suppl 1).
6Feinberg M. Hidden dangers of incompletely suppressive antiretroviral therapy.Lan cet 1997；349: 1408.
7CAESAR Coordinating Committee. Randomised trail of addition of lamivudine of lamivudine plus Ioviride to zidovudine-containing regimens for patients with. HIV-1 infection:the CAESAR trial.Lancet 1997；349:1413.
8Hammer SM. Katzenstein DA, Hughes MD. et al. A trial comparing nucleoside monotherapy ,with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 50O per cubic millimeter. N Engl J Med 1996； 335: 1081.
9Gulick RM, Mellors L Havlir D, et al. Potent and sustained antiretroviral activity of indinavir (1DV),zidovudine (ZDV)and lamivudine (3TC)[abstract Th.B.931],In:proceedings and abstracts of the 11th International Conference on AIDS:July 7-12,1996；Vancouver (BC).
10D'Aquila RT, Hughes MD. Johnson VA, et al Nevirapioe. zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. Ann Intem Med 1996； 124: 1019.
